HomeBMRN • NASDAQ
Biomarin Pharmaceutical Inc
$87.34
After Hours:
$87.34
(0.00%)0.00
Closed: Mar 28, 5:20:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$88.61
Day range
$86.65 - $88.66
Year range
$76.02 - $100.38
Market cap
16.48B USD
Avg Volume
1.43M
P/E ratio
99.82
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
646.21M20.22%
Operating expense
276.26M15.88%
Net income
20.38M8,282.73%
Net profit margin
3.156,400.00%
Earnings per share
0.4935.25%
EBITDA
55.08M132.87%
Effective tax rate
-5.42%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
1.07B-16.86%
Total assets
6.84B7.32%
Total liabilities
1.89B6.67%
Total equity
4.95B
Shares outstanding
188.68M
Price to book
3.38
Return on assets
1.04%
Return on capital
1.17%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
20.38M8,282.73%
Cash from operations
27.48M305.00%
Cash from investing
-64.96M-18.74%
Cash from financing
10.84M-0.27%
Net change in cash
-30.29M18.11%
Free cash flow
19.90M-51.65%
About
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Founded
Mar 1997
Employees
3,401
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu